BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wellhöner F, Döscher N, Tergast TL, Vital M, Plumeier I, Kahl S, Potthoff A, Manns MP, Maasoumy B, Wedemeyer H, Cornberg M, Pieper DH, Heidrich B. The impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patients. Scand J Gastroenterol 2019;54:1033-41. [PMID: 31361979 DOI: 10.1080/00365521.2019.1647280] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Wellhöner F, Döscher N, Woelfl F, Vital M, Plumeier I, Kahl S, Potthoff A, Manns MP, Pieper DH, Cornberg M, Wedemeyer H, Heidrich B. Eradication of Chronic HCV Infection: Improvement of Dysbiosis Only in Patients Without Liver Cirrhosis. Hepatology 2021;74:72-82. [PMID: 33411981 DOI: 10.1002/hep.31700] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Gustot T, Stadlbauer V, Laleman W, Alessandria C, Thursz M. Transition to decompensation and acute-on-chronic liver failure: Role of predisposing factors and precipitating events. J Hepatol 2021;75 Suppl 1:S36-48. [PMID: 34039491 DOI: 10.1016/j.jhep.2020.12.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 De Roza MA, Kai L, Kam JW, Chan YH, Kwek A, Ang TL, Hsiang JC. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis. World J Gastroenterol 2019; 25(33): 4933-4944 [PMID: 31543684 DOI: 10.3748/wjg.v25.i33.4933] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
4 Le Bastard Q, Berthelot L, Soulillou JP, Montassier E. Impact of non-antibiotic drugs on the human intestinal microbiome. Expert Rev Mol Diagn 2021;:1-14. [PMID: 34225544 DOI: 10.1080/14737159.2021.1952075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Hillert A, Schultalbers M, Tergast TL, Vonberg RP, Rademacher J, Wedemeyer H, Cornberg M, Ziesing S, Maasoumy B, Höner Zu Siederdissen C. Antimicrobial resistance in patients with decompensated liver cirrhosis and bacterial infections in a tertiary center in Northern Germany. BMC Gastroenterol 2021;21:296. [PMID: 34284732 DOI: 10.1186/s12876-021-01871-w] [Reference Citation Analysis]
6 El-Mowafy M, Elgaml A, El-Mesery M, Sultan S, Ahmed TAE, Gomaa AI, Aly M, Mottawea W. Changes of Gut-Microbiota-Liver Axis in Hepatitis C Virus Infection. Biology (Basel) 2021;10:55. [PMID: 33451143 DOI: 10.3390/biology10010055] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
7 Inoue T, Funatsu Y, Ohnishi M, Isogawa M, Kawashima K, Tanaka M, Moriya K, Kawaratani H, Momoda R, Iio E, Nakagawa H, Suzuki Y, Matsuura K, Fujiwara K, Nakajima A, Yoshiji H, Nakayama J, Tanaka Y. Bile acid dysmetabolism in the gut-microbiota-liver axis under hepatitis C virus infection. Liver Int 2021. [PMID: 34411400 DOI: 10.1111/liv.15041] [Reference Citation Analysis]
8 Sultan S, El-Mowafy M, Elgaml A, El-Mesery M, El Shabrawi A, Elegezy M, Hammami R, Mottawea W. Alterations of the Treatment-Naive Gut Microbiome in Newly Diagnosed Hepatitis C Virus Infection.ACS Infect Dis. 2021;7:1059-1068. [PMID: 33119247 DOI: 10.1021/acsinfecdis.0c00432] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]